Form 4: Teva Pharmaceutical Industries Executive Receives Restricted Share Units

Evan Lippman, EVP of Business Development at Teva Pharmaceutical Industries, was granted restricted share units on May 14, 2025, according to a Form 4 filing.

Summary

• Evan Lippman, an Executive Vice President at Teva Pharmaceutical Industries, received restricted share units on May 14, 2025.
• The filing details the grant of two tranches of restricted share units.
• The first grant consists of 47,365 restricted share units, vesting in installments from May 14, 2026, to May 14, 2029.
• The second grant consists of 148,016 restricted share units, vesting in installments from May 14, 2026, to May 14, 2028.
• Each restricted share unit represents the right to receive one ordinary share or its cash value.
• The ordinary shares may be represented by American Depositary Shares (ADS).
• The reporting person's holdings following the reported transactions include 47,365 and 148,016 restricted share units.

Sentiment

Score: 6

Explanation: The document is a routine regulatory filing related to executive compensation, indicating a neutral sentiment. It reflects standard corporate governance practices.

Positives

• The grant of restricted share units aligns the executive's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the restricted share units.

Industry Context

Granting restricted share units is a common practice in the pharmaceutical industry to incentivize and retain key executives.

Comparison to Industry Standards

• Equity compensation is a standard practice among pharmaceutical companies such as Pfizer, Novartis, and Johnson & Johnson to align executive interests with shareholder value.
• The vesting schedules are typical for restricted share unit grants, encouraging long-term performance and retention.

Stakeholder Impact

• The grant of restricted share units aligns the executive's interests with those of the shareholders, potentially leading to better company performance.
• Employees may view the grant as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

Restricted Share Units, Teva Pharmaceutical Industries, Form 4, Executive Compensation, Evan Lippman, Equity, Vesting